PTCT
PTC Therapeutics Inc
65.30$
-0.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.1% | 96.7% | 97.0% | 63.6% | 28.7% | 48.0% | 55.8% | 39.9% | 40.7% | 64.3% | 80.1% | 78.4% | |
| 94.6% | 92.1% | 86.0% | 48.8% | 20.3% | 17.7% | 9.5% | 39.9% | 16.4% | 31.3% | 45.7% | 34.0% | |
| 94.6% | 92.1% | 86.0% | 48.8% | 20.3% | 42.3% | 50.0% | 39.9% | 24.1% | 46.2% | 66.8% | 67.1% | |
| 1.3% | 3.0% | 9.3% | 10.3% | 6.1% | 3.4% | 3.2% | 5.7% | 9.1% | 8.5% | 9.3% | 6.3% | |
| 0.0% | 0.0% | 0.6% | 2.7% | 1.4% | 1.2% | 0.8% | 0.8% | 1.3% | 1.6% | 1.4% | 2.7% | |
| 2.7% | 2.4% | 2.8% | 2.1% | 1.1% | 1.3% | 1.5% | 6.7% | 4.3% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 34.0% | 7.4% | 5.1% | 3.7% | 4.2% | 4.8% | 4.3% | 4.8% | 2.8% | |
| 0.0% | 0.0% | 0.0% | 34.0% | 62.6% | 43.8% | 32.4% | 37.4% | 41.4% | 20.0% | 7.0% | 13.4% | |
| 10.4% | 18.9% | 55.6% | 60.1% | 68.7% | 63.4% | 78.2% | 99.9% | 120.3% | 143.2% | 164.4% | 107.1% | |
| 9.7% | 12.3% | 18.4% | 20.9% | 14.9% | 14.5% | 12.6% | 26.3% | 23.8% | 31.8% | 34.1% | 33.4% | |
| – | 25.0% | 15.2% | 15.6% | 1.0% | 1.5% | 0.4% | 8.2% | 5.0% | 11.1% | 15.9% | 20.2% | |
| 1.2% | 3.2% | 2.3% | 3.9% | 0.5% | 0.6% | 0.8% | 1.2% | 1.6% | 0.3% | 1.0% | 1.6% | |
| 0.0% | 25.7% | 36.5% | 37.0% | 12.6% | 18.1% | 14.0% | 14.5% | 33.5% | 100.4% | 123.7% | 69.9% | |
| 89.6% | 81.1% | 44.4% | 39.9% | 31.3% | 36.6% | 21.8% | 0.1% | -20.3% | -43.2% | -64.4% | -7.1% | |
| -126.8% | -161.1% | -272.9% | -207.9% | -83.9% | -73.3% | -73.8% | -108.3% | -155.8% | -173.2% | -213.9% | -102.3% | |
| 9.5% | 9.1% | 12.6% | 10.0% | 4.2% | 3.6% | 3.0% | 3.6% | 4.2% | 3.9% | 4.5% | 3.0% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.